Skip to main content

Table 1 Patients’ characteristics

From: Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

Characteristic n % Years
Age: median (range)    70 (49–86)
Sex    
  Female 40 49  
  Male 42 51  
ECOG    
  0 31 38  
  1 43 52  
  2 8 10  
Comorbidity (clinically relevant)    (1 missing)
  yes 66 81  
Primary tumor    
  Colon 56 68  
  Rectum 26 32  
Resected primary tumor 66 80  
Prior radiotherapy for rectal primary 12 15  
Adjuvant chemotherapy 19 23  
Metastases    (1 missing)
  synchronous metastases 58 72  
  metastatic sites    
  1 34 42  
  >1 47 58  
  liver metastases 65 80  
Prognosis score acc. to Kohne et al.    (8 missing)
  low risk 64 86  
  high risk 10 14  
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group performance status, n number.